Globally, 415 million adults were living with diabetes in 2015 and this figure is predicted to rise to 642 million by 2040, representing approximately 10% of the world’s population aged between 20 and 79.
Our team in our Vascular Biology Program are excited to have developed a new drug, known as CD5-2, that could potentially treat diabetic retinopathy, a condition that leads to vision loss.Read More
Our Molecular Cardiology Program has made a game-changing discovery using state-of-the-art technology which is literally saving lives.
You can Read about this groundbreaking research and how families like Michael’s may be spared the trauma of losing a young, healthy loved one.Donate Now
A group of international researchers, led by three from Centenary, now has a better understanding of how blood clots are formed. The results of their study have recently been published in the peer-reviewed scientific journal eLife. The development has the potential to be life-changing for many Australians.
You can read about the outcome of the study and why this area of research is so important.Donate Now
Dr Ben Roediger, Head of Centenary’s Skin Imaging and Inflammation Laboratory. He is investigating the mechanisms by which inflammation contributes to chronic inflammatory diseases, including allergic disease and cancer.Donate Now
Meet Dr Jessamy Tiffen from our Melanoma Immunology and Oncology Program who is working to reduce the impact of cancer. In particular Melanoma on individuals, families and the community as a whole.Donate Now